

Ref: Syn/CS/SE/BM/July/2019-20/39

Syngene International Limited
Biocon Park SEZ, Bommasandra IV Phase,
Jigani Link Road, Bangalore 560 099,
India.
T +91 80 2808 2808
F +91 80 4014 3150 / 2852 3423
CIN No. L85110KA1993PLC014937
www.syngeneintl.com

July 24, 2019

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
---	---

Dear Sir/Madam,

Subject: Change in the Board of Directors of the Company

Pursuant to the provisions of regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you the following changes in the Board of Directors of the Company:

1. Retirement of Mr. Russel Walls (DIN: 03528496) and Mr. Suresh Talwar (DIN: 00001456) as independent directors of the Company in accordance with the resolution passed through Postal Ballot by members on March 5, 2019, to be effective from conclusion of the 26th Annual General Meeting to be held on July 24, 2019.
2. Appointment of Ms. Sharmila Karve as Additional Director (Independent) on the Board of Directors of the Company, for a period of three years commencing from August 1, 2019, till the conclusion of the Annual General Meeting proposed to be held in 2022, subject to approval of shareholders.
3. Appointment of Dr. Carl Decicco as Additional Director (Independent) on the Board of Directors of the Company, for a period of three years commencing from the date of allotment of his Director Identification Number (DIN), till the conclusion of the Annual General Meeting proposed to be held in 2022, subject to approval of shareholders.

The brief profiles of Ms. Sharmila Karve and Dr. Carl Decicco are enclosed.

This intimation will also be available on website of the Company www.syngeneintl.com.

This is for your information and record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**



Priyadarshini Mahapatra
Company Secretary & Compliance Officer



13

1. Ms. Sharmila Karve- Brief Profile



Based in Mumbai, India, Sharmila Karve joined Pricewaterhouse Coopers (PwC) in 1985 as an Articled Student and qualified in 1988 and was promoted to Assistant Manager immediately thereafter. She worked with the firm until May 1991 when she left for personal reasons.

She re-joined the firm in May 1994 and was admitted to the partnership in May 1997. She was one of the youngest partners to be promoted after just 6 years of post-qualification working experience. After becoming a partner, she worked as engagement partner on various large Indian and multinational clients. She was the first female partner to be elected to the POC and to be appointed as the Chief Ethics Officer.

After the events of 2009, she was appointed as the Assurance Leader of the firm. She also was inducted onto the ILT after she took over the TAL role. She navigated the Assurance practice through one of the most difficult times in the history of the firm. She and her partners were able to keep the clients, staff and partners together and she considers this as one of her biggest achievements. She worked along with the lawyers and various people in the firm to arrive at the terms of settlement with the PCAOB and the SEC. She took over the Assurance Risk & Quality Leader role in April 2012.

In her new role as Global Diversity Leader since December 2016, Sharmila focused her efforts on bringing more diversity throughout the PwC network. She has resigned from the firm as on June 30, 2019.

Sharmila Karve is not related to any of the directors of the Company.

2. Dr. Carl Decicco- Brief Profile



Dr. Carl P. Decicco, Ph.D., serves as Member of Advisory Committee at Allied-Bristol Life Sciences, LLC. Dr. Decicco serves as the Head of Discovery at BMS and is responsible for the discovery and advancement of drug candidates for clinical studies. He also has oversight of the Drug Safety Evaluation team that provides supporting studies for all levels of clinical investigation.

He has 22 years of experience in the pharmaceutical industry. With his teams, he has delivered over 140 compounds into development, several of which have advanced into late stage clinical testing. He has been part of the BMS leadership team that has achieved 14 NDA's over the last 10 years.

He completed post-doctoral studies with Professor EJ Corey at Harvard University, was a teaching fellow at the University of British Columbia and obtained his Ph.D. with Professor Gordon Lange in Organic Chemistry from the Guelph-Waterloo Center in Ontario, Canada.

Dr. Carl P. Decicco is not related to any of the directors of the Company.